4.5 Review

Microarray-based DNA profiling to study genomic aberrations

Journal

IUBMB LIFE
Volume 60, Issue 7, Pages 437-440

Publisher

WILEY-BLACKWELL
DOI: 10.1002/iub.57

Keywords

microarray; genetic variation; single-nucleotide polymorphism; genotyping; genome-wide association studies

Ask authors/readers for more resources

High throughput microarrays were initially developed to analyse the expression of many RNA transcripts in parallel. The technology has since been adapted to a variety of applications, one of which is the analysis of the genome to study DNA dosage and sequence content. Advances in microarray fabrication and completion of large-scale genome sequencing projects have enabled the rapid development of affordable array-based methods for high-resolution genome-wide assessment of DNA alterations. This review will describe the evolution of microarray assays to study genomic aberrations and will highlight how they have enabled researchers to gain insight into the biology of human diseases and how they will benefit research in the future. (c) 2008 IUBMB.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance

Felicity Newell, Ines Pires da Silva, Peter A. Johansson, Alexander M. Menzies, James S. Wilmott, Venkateswar Addala, Matteo S. Carlino, Helen Rizos, Katia Nones, Jarem J. Edwards, Vanessa Lakis, Stephen H. Kazakoff, Pamela Mukhopadhyay, Peter M. Ferguson, Conrad Leonard, Lambros T. Koufariotis, Scott Wood, Christian U. Blank, John F. Thompson, Andrew J. Spillane, Robyn P. M. Saw, Kerwin F. Shannon, John Pearson, Graham J. Mann, Nicholas K. Hayward, Richard A. Scolyer, Nicola Waddell, Georgina Long

Summary: This study examines the relationship between various factors and the response to immunotherapy in patients with advanced cutaneous melanoma. The results identify several factors associated with response and develop a multivariable model for predicting response. However, the study also indicates the presence of intratumor and intertumor heterogeneity in response to immunotherapy and the lack of clear biological mechanisms explaining non-predicted responses.

CANCER CELL (2022)

Article Oncology

Combined Inhibition of G9a and EZH2 Suppresses Tumor Growth via Synergistic Induction of IL24-Mediated Apoptosis

Francesco Casciello, Gregory M. Kelly, Priya Ramarao-Milne, Nabilah Kamal, Teneale A. Stewart, Pamela Mukhopadhyay, Stephen H. Kazakoff, Mariska Miranda, Dorim Kim, Felicity M. Davis, Nicholas K. Hayward, Paula M. Vertino, Nicola Waddell, Frank Gannon, Jason S. Lee

Summary: G9a and EZH2, two histone methyltransferases commonly upregulated in several cancer types, cooperatively repress molecular pathways responsible for tumor cell death, and their simultaneous inhibition can induce tumor cell death.

CANCER RESEARCH (2022)

Article Genetics & Heredity

Community input in a genomic health implementation program: Perspectives of a community advisory group

Miranda E. Vidgen, Katrina Cutler, Jessica Bean, David Bunker, Lindsay F. Fowles, Louise Healy, Gary Hondow, Satrio Nindyo Istiko, Aideen M. McInerney-Leo, Gregory Pratt, Deborah Robins, Nicola Waddell, Erin Evans

Summary: Consumer and community engagement is crucial for the implementation of genomics into health services and research. The Queensland Genomics program successfully utilized a Community Advisory Group (CAG) to provide advice and leadership in community-focused activities. However, limitations were faced due to a lack of mechanisms for implementing consumer and community engagement in the program's projects.

FRONTIERS IN GENETICS (2022)

Article Oncology

Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels

P. Ramarao-Milne, O. Kondrashova, A. -M. Patch, K. Nones, L. T. Koufariotis, F. Newell, V. Addala, V. Lakis, O. Holmes, C. Leonard, S. Wood, Q. Xu, P. Mukhopadhyay, M. M. Naeini, D. Steinfort, J. P. Williamson, M. Bint, C. Pahoff, P. T. Nguyen, S. Twaddell, D. Arnold, C. Grainge, F. Basirzadeh, D. Fielding, A. J. Dalley, H. Chittoory, P. T. Simpson, L. G. Aoude, V. F. Bonazzi, K. Patel, A. P. Barbour, D. A. Fennell, B. W. Robinson, J. Creaney, G. Hollway, J. V. Pearson, N. Waddell

Summary: This study explored drug repurposing opportunities using the Cancer Genome Interpreter and whole-genome sequencing. The ability of different sequencing methods, including whole-exome sequencing and comprehensive sequencing panels, to detect actionable mutations, tumor mutation burden, and microsatellite instability was compared. The results revealed shared biomarkers among different solid tumor types, with comprehensive panels identifying the majority of actionable mutations and whole-genome sequencing detecting more candidate actionable mutations.

ESMO OPEN (2022)

Article Gastroenterology & Hepatology

Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples

Miriam Redegalli, Greta Grassini, Gilda Magliacane, Lorenza Pecciarini, Marco Schiavo Lena, Chanel E. Smart, Rebecca L. Johnston, Nicola Waddell, Roberta Maestro, Marina Macchini, Giulia Orsi, Maria Chiara Petrone, Gemma Rossi, Gianpaolo Balzano, Massimo Falconi, Paolo G. Arcidiacono, Michele Reni, Claudio Doglioni, Maria Giulia Cangi

Summary: This study demonstrates the feasibility of using NGS approach for comprehensive molecular profiling of PDAC patients, regardless of their surgical eligibility. The mutational profiles detected in cytologic samples showed high concordance with the corresponding histologic specimens obtained after surgery, and actionable mutations were identified in a significant proportion of patients.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Clinical Neurology

Early cost-utility analysis of genetically guided therapy for patients with drug-resistant epilepsy

Louisa G. Gordon, Thomas M. Elliott, Carmen Bennett, Georgina Hollway, Nicola Waddell, Lata Vadlamudi

Summary: This study assessed the cost-effectiveness of a pharmacogenomics panel for patients with drug-resistant epilepsy and found that it could potentially be cost-effective in the Australian healthcare system.

EPILEPSIA (2022)

Article Genetics & Heredity

Analysis of hereditary cancer gene variant classifications from ClinVar indicates a need for regular reassessment of clinical assertions

Aimee L. Davidson, Olga Kondrashova, Conrad Leonard, Scott Wood, Emma Tudini, Georgina E. Hollway, John Pearson, Felicity Newell, Amanda B. Spurdle, Nicola Waddell

Summary: This study examined how variant classification changes over time using the ClinVar database. The findings suggest that there are significant changes in variant classification between consecutive semi-annual releases, emphasizing the need for regular reassessment of clinical variant interpretations.

HUMAN MUTATION (2022)

Article Oncology

Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

Felicity Newell, Peter A. Johansson, James S. Wilmott, Katia Nones, Vanessa Lakis, Antonia L. Pritchard, Serigne N. Lo, Robert Rawson, Stephen H. Kazakoff, Andrew J. Colebatch, Lambros T. Koufariotis, Peter M. Ferguson, Scott Wood, Conrad Leonard, Matthew H. Law, Kelly M. Brooks, Natasa Broit, Jane M. Palmer, Kasey L. Couts, Ismael A. Vergara, Georgina Long, Andrew P. Barbour, Omgo E. Nieweg, Brindha Shivalingam, William A. Robinson, Jonathan R. Stretch, Andrew J. Spillane, Robyn P. M. Saw, Kerwin F. Shannon, John F. Thompson, Graham J. Mann, John Pearson, Richard A. Scolyer, Nicola Waddell, Nicholas K. Hayward

Summary: This is the largest whole-genome analysis of melanoma to date, comprehensively comparing the genomics of the four major melanoma subtypes. This study highlights both similarities and differences between the subtypes, providing insights into the etiology and biology of melanoma.

CANCER DISCOVERY (2022)

Article Multidisciplinary Sciences

Heritable defects in telomere and mitotic function selectively predispose to sarcomas

Mandy L. Ballinger, Swetansu Pattnaik, Piyushkumar A. Mundra, Milita Zaheed, Emma Rath, Peter Priestley, Jonathan Baber, Isabelle Ray-Coquard, Nicholas Isambert, Sylvain Causeret, Winette T. A. van der Graaf, Ajay Puri, Florence Duffaud, Axel Le Cesne, Beatrice Seddon, Coonoor Chandrasekar, Joshua D. Schiffman, Andrew S. Brohl, Paul A. James, Jean-Emmanuel Kurtz, Nicolas Penel, Ola Myklebost, Leonardo A. Meza-Zepeda, Hilda Pickett, Maya Kansara, Nicola Waddell, Olga Kondrashova, John Pearson, Andrew P. Barbour, Shuai Li, Tuong L. Nguyen, Diane Fatkin, Robert M. Graham, Eleni Giannoulatou, Melissa J. Green, Warren Kaplan, Shyamsundar Ravishankar, Joseph Copty, Joseph E. Powell, Edwin Cuppen, Kristel van Eijk, Jan Veldink, Jin-Hee Ahn, Jeong Eun Kim, R. Lor Randall, Kathy Tucker, Ian Judson, Rajiv Sarin, Thomas Ludwig, Emmanuelle Genin, Jean-Francois Deleuze, Michelle Haber, Glenn Marshall, Murray J. Cairns, Jean-Yves Blay, David M. Thomas

Summary: Cancer genetics has focused on epithelial malignancies, but this study explores specific pathways related to sarcomas, rare malignancies derived from embryonic mesoderm. Germline sequencing of sporadic cases and healthy controls reveals two sarcoma-specific pathways involved in mitotic and telomere functions. Centrosome gene variants are linked to specific tumors, while heritable defects in the shelterin complex increase susceptibility to sarcomas, melanomas, and thyroid cancers. These findings highlight the role of heritable defects in mitotic and telomere biology in sarcoma risk.

SCIENCE (2023)

Article Genetics & Heredity

Australian Genomics: Outcomes of a 5-year national program to accelerate the integration of genomics in healthcare

Zornitza Stark, Tiffany Boughtwood, Matilda Haas, Jeffrey Braithwaite, Clara L. Gaff, Ilias Goranitis, Amanda B. Spurdle, David P. Hansen, Oliver Hofmann, Nigel Laing, Sylvia Metcalfe, Ainsley J. Newson, Hamish S. Scott, Natalie Thorne, Robyn L. Ward, Marcel E. Dinger, Stephanie Best, Janet C. Long, Sean M. Grimmond, John Pearson, Nicola Waddell, Christopher P. Barnett, Matthew Cook, Michael Field, David Fielding, Stephen B. Fox, Jozef Gecz, Adam Jaffe, Richard J. Leventer, Paul J. Lockhart, Sebastian Lunke, Andrew J. Mallett, Julie McGaughran, Linda Mileshkin, Katia Nones, Tony Roscioli, Ingrid E. Scheffer, Christopher Semsarian, Cas Simons, David M. Thomas, David R. Thorburn, Richard Tothill, Deborah White, Sally Dunwoodie, Peter T. Simpson, Peta Phillips, Marie-Jo Brion, Keri Finlay, Michael CJ. Quinn, Tessa Mattiske, Emma Tudini, Kirsten Boggs, Sean Murray, Kathy Wells, John Cannings, Andrew H. Sinclair, John Christodoulou, Kathryn N. North

Summary: Australian Genomics is a national collaborative partnership that aims to integrate genomics into healthcare through a whole-of-system approach. It has evaluated genomic testing outcomes in over 5,200 individuals across rare disease and cancer studies and provided evidence-based changes in policy and practice, resulting in government funding and access to genomic tests. It has also developed national skills, infrastructure, policy, and data resources to support data sharing and improve clinical genomic delivery.

AMERICAN JOURNAL OF HUMAN GENETICS (2023)

Article Oncology

Intratumoral CD16± Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy

Hansol Lee, Angela L. Ferguson, Camelia Quek, Ismael A. Vergara, Ines Pires daSilva, Ruth Allen, Tuba Nur Gide, Jordan W. Conway, Lambros T. Koufariotis, Nicholas K. Hayward, Nicola Waddell, Matteo S. Carlino, Alexander M. Menzies, Robyn P. M. Saw, Elena Shklovskaya, Helen Rizos, Serigne Lo, Richard A. Scolyer, Georgina V. Long, Umaimaintha Palendira, James S. Wilmott

Summary: This study characterized intratumoral macrophage populations in melanoma biopsies and investigated the association between CD16-expressing macrophage densities and treatment outcomes for patients receiving anti-PD-1 monotherapy or a combination with anti-CTLA-4. The results showed that patients who responded to combination therapy had higher CD16 macrophage densities compared to those who did not respond. Additionally, patients with high intratumoral densities of CD16 macrophages had a significantly longer progression-free survival. These findings suggest that CD16 macrophages may serve as a potential biomarker for response to combination immunotherapies in metastatic melanoma patients.

CLINICAL CANCER RESEARCH (2023)

Article Oncology

Efficient detection and monitoring of pediatric brain malignancies with liquid biopsy based on patient-specific somatic mutation screening

Marija Kojic, Mellissa K. Maybury, Nicola Waddell, Lambros T. Koufariotis, Venkateswar Addala, Amanda Millar, Scott Wood, John Pearson, Jordan R. Hansford, Tim Hassall, Brandon J. Wainwright

Summary: Liquid biopsy is a promising approach for detecting and monitoring pediatric brain cancer by screening body fluids for the presence of ctDNA. We developed personalized mutation-based liquid biopsy assays which showed great potential for predicting tumor progression and response to treatment.

NEURO-ONCOLOGY (2023)

Review Oncology

Computational immunogenomic approaches to predict response to cancer immunotherapies

Venkateswar Addala, Felicity Newell, John V. Pearson, Alec Redwood, Bruce W. Robinson, Jenette Creaney, Nicola Waddell

Summary: Cancer immunogenomics is an emerging field that combines genomics and immunology to better understand and improve cancer immunotherapy. The use of large-scale genomic collaborations and advanced sequencing techniques has allowed researchers to identify clinically actionable alterations and predictive biomarkers in various types of cancer. Computational approaches and machine learning algorithms have been developed to analyze sequencing data and provide clinically useful information. However, there is still a need to fully understand the potential and limitations of these approaches in improving patient outcomes.

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

Correction Medicine, Research & Experimental

IL-10-producing Th1 cells possess a distinct molecular signature in malaria (vol 133, e153733, 2023)

Chelsea L. Edwards, Susanna S. Ng, Fabian de Labastida Rivera, Dillon Corvino, Jessica A. Engel, Marcela Montes de Oca, Luzia Bukali, Teija C. M. Frame, Patrick T. Bunn, Shashi Bhushan Chauhan, Siddharth Sankar Singh, Yulin Wang, Jinrui Na, Fiona H. Amante, Jessica R. Loughland, Megan S. F. Soon, Nicola Waddell, Pamela Mukhopadhay, Lambros T. Koufariotis, Rebecca L. Johnston, Jason S. Lee, Rachel Kuns, Ping Zhang, Michelle J. Boyle, Geoffrey R. Hill, James S. McCarthy, Rajiv Kumar, Christian R. Engwerda

JOURNAL OF CLINICAL INVESTIGATION (2023)

Article Immunology

Increased amphiregulin expression by CD4+ T cells from individuals with asymptomatic Leishmania donovani infection

Siddharth Sankar Singh, Shashi Bhushan Chauhan, Susanna S. S. Ng, Dillon Corvino, Fabian de Labastida Rivera, Jessica A. Engel, Nic Waddell, Pamela Mukhopadhay, Rebecca L. Johnston, Lambros T. Koufariotis, Susanne Nylen, Om Prakash Singh, Christian R. Engwerda, Rajiv Kumar, Shyam Sundar

Summary: This study identified increased expression of AREG in CD4(+) T cells from individuals with asymptomatic L. donovani infection, suggesting the presence of an ongoing inflammatory response and highlighting the potential role of AREG in preventing inflammation-induced tissue damage and subsequent disease in asymptomatic individuals.

CLINICAL & TRANSLATIONAL IMMUNOLOGY (2022)

No Data Available